---
title: "COVID-19 Burden in Adults with Systemic Autoimmune Rheumatic Diseases in Quebec, 2020–2023"
id: "medrxiv-15-comparative-burden-of-covid-19-in-adults-with-rheumatic-diseases-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-comparative-burden-of-covid-19-in-adults-with-rheumatic-diseases-and"
content_type: "clinical_feed_article"
specialty: "Rheumatology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.21.26363556v1?rss=1"
published_at: "2026-09-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# COVID-19 Burden in Adults with Systemic Autoimmune Rheumatic Diseases in Quebec, 2020–2023
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-comparative-burden-of-covid-19-in-adults-with-rheumatic-diseases-and
- **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.21.26363556v1?rss=1)
- **Published At:** 2026-09-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This population-based cohort study compared COVID-19 incidence and severe outcomes in adults with **systemic autoimmune rheumatic diseases (SARDs)**, adults with chronic comorbidities, and adults without comorbidities in Quebec between March 2020 and April 2023. - The study used administrative health datasets to estimate crude and age- and sex-standardized SARS-CoV-2 infection and severe COVID-19 incidence and to calculate adjusted hazard ratios (aHRs) for infection, hospitalization, and intensive care unit admission or death (ICU/death) across three pandemic periods: pre-vaccination, vaccination pre-Omicron, and Omicron. - Cohorts included 81,434 adults with SARDs, 2,020,356 adults with comorbidities, and 3,144,700 adults without comorbidities. - Although adjusted infection rates were similar, the **SARDs** cohort experienced substantially higher risks of hospitalization and ICU/death compared with adults without comorbidities during the pre-vaccination period (hospitalization aHR 3.4, 95% CI 2.8–4.1; ICU/death aHR 4.0, 95% CI 2.8–5.7) and these elevated risks persisted through the Omicron period (hospitalization aHR 4.5, 95% CI 4.0–4.9; ICU/death aHR 4.4, 95% CI 3.6–5.4). - Within SARDs, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus contributed the largest burden; hospitalization and mortality for younger rheumatoid arthritis patients were comparable to those of older healthy adults. - Patients treated with highly immunosuppressive agents—specifically **rituximab** or **mycophenolate**—had the highest risks of hospitalization and ICU/death, particularly during the Omicron period (hospitalization aHR 11.9, 95% CI 9.9–14.3; ICU/death aHR 17.6, 95% CI 13.0–23.9). - Data are held by Quebec health authorities and are not publicly available due to privacy restrictions; study code is available from the authors on request. The research was conducted under a legal public health mandate with ethics approval and waived informed consent. - The authors conclude that individuals with **SARDs**, especially those receiving highly immunosuppressive therapies, experienced an elevated COVID-19 burden across the pandemic and should be considered for prioritization in future public health emergency planning.
## Clinical Analysis & Structured Key Points
Comparative Burden of COVID-19 in Adults with Rheumatic Diseases and Immunocompetent Individuals: A Population-Based Cohort Study in Quebec, Canada, 2020-2023 | medRxiv Skip to main content Comparative Burden of COVID-19 in Adults with Rheumatic Diseases and Immunocompetent Individuals: A Population-Based Cohort Study in Quebec, Canada, 2020-2023 View ORCID Profile Sara Carazo , View ORCID Profile Ines Colmegna , View ORCID Profile Sasha Bernatsky , View ORCID Profile Paul R Fortin , View ORCID Profile Sonia Jean , View ORCID Profile Denis Talbot , View ORCID Profile Louis Rochette , View ORCID Profile Charles-Antoine Guay , View ORCID Profile Michael Libman , Michael Desjardins , View ORCID Profile Caroline Quach , View ORCID Profile Danuta M Skowronski , View ORCID Profile Gaston De Serres , Canadian Immunization Research Network doi: https://doi.org/10.64898/2026.09.21.26363556 Sara Carazo 1 Institut national de santé publique du Québec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sara Carazo For correspondence: sara.carazo{at}inspq.qc.ca Ines Colmegna 2 The Research Institute of the McGill University Health Centre; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ines Colmegna Sasha Bernatsky 2 The Research Institute of the McGill University Health Centre; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sasha Bernatsky Paul R Fortin 3 Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Paul R Fortin Sonia Jean 1 Institut national de santé publique du Québec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sonia Jean Denis Talbot 4 Laval University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Denis Talbot Louis Rochette 1 Institut national de santé publique du Québec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Louis Rochette Charles-Antoine Guay 1 Institut national de santé publique du Québec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Charles-Antoine Guay Michael Libman 5 McGill University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Michael Libman Michael Desjardins 6 University of Montreal; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Caroline Quach 6 University of Montreal; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Caroline Quach Danuta M Skowronski 7 BC Centre for Disease Control Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Danuta M Skowronski Gaston De Serres 4 Laval University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Gaston De Serres Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Introduction: Across major phases of the COVID-19 pandemic (March 2020-April 2023), we compared the burden of severe COVID-19 among individuals with systemic autoimmune rheumatic diseases (SARDs) versus immunocompetent individuals with and without comorbidities. Methods: This population-based cohort study used administrative datasets to estimate crude and age- and sex-standardized SARS-CoV-2 and severe COVID-19 incidences among adults >18 years with SARDs, chronic comorbidities, or no comorbidities. Relative to the latter, we used Cox models to derive adjusted hazard ratios (aHRs) for infection, hospitalization, and intensive care unit admission or death (ICU/death) during the pre-vaccination (March-December 2020), vaccination pre-Omicron (December 2020-December 2021), and Omicron (December 2021-April 2023) periods. Results: We included 81,434 adults with SARDs, and 2,020,356 with comorbidities versus 3,144,700 without comorbidities. Despite similar adjusted infection rates, the SARDS cohort had higher risks of hospitalization and ICU/death during the pre-vaccination period (aHRs: 3.4, 95%CI:2.8-4.1; and 4.0, 95%CI:2.8-5.7, respectively), persisting through the Omicron period (aHRs: 4.5, 95%CI:4.0-4.9; and 4.4, 95%CI:3.6-5.4, respectively). Among SARDS, rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus contributed highest burden, with comparable hospitalization and mortality rates among younger rheumatoid arthritis versus healthy older adults. Highly immunosuppressive rituximab- or mycophenolate-treated patients had highest hospitalization and ICU/death risks, particularly during the Omicron period (aHRs: 11.9, 95%CI:9.9-14.3; and 17.6, 95%CI:13.0-23.9, respectively). Conclusion: Individuals with SARDs, especially receiving highly immunosuppressive therapies, experienced elevated COVID-19 burden and severe outcome risks throughout the pandemic, warranting their prioritized consideration during future public health emergencies. Competing Interest Statement SC and CAG report funding from the Ministère de la Santé et des Services sociaux du Québec for this work paid to their institution. SC reports funding from the Public Health Agency of Canada for unrelated work paid to her institution. CAG reports project grants from the Canadian Institutes of Health Research for unrelated research, a post-doctoral research grant from Pediatric Outcomes Improvement through Coordination of Research Networks and a grant from Fonds de recherche du Québec - Santé for supplementary residency in research. DMS has received grants from the Public Health Agency of Canada, Canadian Institutes of Health Research, Pacific Public Health Foundation and the Michael Smith Foundation for Health Research for unrelated work, paid to her institution. GDS report funding from the Canadian Immunization Research Network for this work, paid to his institution. Other authors have no conflict of interest to declare. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was conducted under the legal mandate of the Quebec National Director of Public Health, under which the requirement for informed consent was waived. The study protocol was approved by the Research Ethics Board of the CHU de Québec-Université Laval. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data are not publicly available due to privacy restrictions. Data are held by the Quebec Ministry of Health and the Régie de l'assurance maladie du Québec (RAMQ), and access is restricted to authorized personnel. Requests for data access should be directed to the Ministère de la Santé et des Services sociaux du Québec. The study code is available from the authors upon reasonable request. Funder Information Declared Canadian Immunization Research Network Ministère de la Santé et des Services sociaux du Québec Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Comparative Burden of COVID-19 in Adults with Rheumatic Diseases and Immunocompetent Individuals: A Population-Based Cohort Study in Quebec, Canada, 2020-2023 Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Comparative Burden of COVID-19 in Adults with Rheumatic Diseases and Immunocompetent Individuals: A Population-Based Cohort Study in Quebec, Canada, 2020-2023 Sara Carazo , Ines Colmegna , Sasha Bernatsky , Paul R Fortin , Sonia Jean , Denis Talbot , Louis Rochette , Charles-Antoine Guay , Michael Libman , Michael Desjardins , Caroline Quach , Danuta M Skowronski , Gaston De Serres , Canadian Immunization Research Network medRxiv 2026.09.21.26363556; doi: https://doi.org/10.64898/2026.09.21.26363556 Share This Article: Copy Citation Tools Comparative Burden of COVID-19 in Adults with Rheumatic Diseases and Immunocompetent Individuals: A Population-Based Cohort Study in Quebec, Canada, 2020-2023 Sara Carazo , Ines Colmegna , Sasha Bernatsky , Paul R Fortin , Sonia Jean , Denis Talbot , Louis Rochette , Charles-Antoine Guay , Michael Libman , Michael Desjardins , Caroline Quach , Danuta M Skowronski , Gaston De Serres , Canadian Immunization Research Network medRxiv 2026.09.21.26363556; doi: https://doi.org/10.64898/2026.09.21.26363556 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (905) Anesthesia (336) Cardiovascular Medicine (4838) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1634) Epidemiology (15986) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7073) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5074) Health Policy (1438) Health Systems and Quality Improvement (1780) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16316) Intensive Care and Critical Care Medicine (1177) Medical Education (674) Medical Ethics (155) Nephrology (727) Neurology (7318) Nursing (370) Nutrition (1088) Obstetrics and Gynecology (1245) Occupational and Environmental Health (1007) Oncology (3625) Ophthalmology (1058) Orthopedics (398) Otolaryngology (458) Pain Medicine (477) Palliative Medicine (140) Pathology (709) Pediatrics (1806) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5927) Public and Global Health (9782) Radiology and Imaging (2438) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (644) Sexual and Reproductive Health (774) Sports Medicine (582) Surgery (783) Toxicology (107) Transplantation (306) Urology (295)
## Related Clinical Research

- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [ABO Blood Groups and Disease Risk: Links to Cardiovascular Disease, Cancer, Diabetes, Malaria, COV](https://medichelpline.com/clinical-feed/pubmed-42574721.md) (DOI: 10.1080/07853890.2026.2710922)
- [CXCL10 rs8878 genotype associates with preserved T cells and 30‑day survival in sepsis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-1-cxcl10-rs8878-identifies-a-genotype-associated-immune-phenotype-linked-to-t.md)
- [Guideline differences in rheumatoid arthritis-associated interstitial lung disease care](https://medichelpline.com/clinical-feed/pubmed-42888356.md) (DOI: 10.1007/s00296-026-06322-x)
- [Detectability floor limits treatment-response labels in rheumatology transcriptomics](https://medichelpline.com/clinical-feed/medrxiv-0-a-detectability-floor-for-treatment-response-labels-in-rheumatology.md)

## Navigation
- [← Back to Rheumatology Feed](https://medichelpline.com/clinical-feed/rheumatology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.